ClinicalTrials.gg
RecruitingNCT07034690OPTIMAUpdated May 4, 2026

Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia

A Phase 4 interventional study of Educational Material and Standard of care in Atherosclerotic Cardiovascular Disease, sponsored by Novartis Pharmaceuticals. Recruiting at 1 site in United Arab Emirates. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Other

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
326
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Atherosclerosis by Novartis — 4 open to participants now, 10 under way, 3 of them phase 3. Atherosclerosis · Novartis.

Planned enrollment
13th of 18
326 · median 426
Started
2025
with 6 others
Phase 4
3 of 27
2 open now
Registered
25th of 27
by date

Among the 27 studies in Atherosclerosis by Novartis, this one is the 13th largest by planned enrollment of the 18 interventional ones that give a count, is one of 7 that started in 2025, is one of 3 in phase 4, and was the 25th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

4 of the 27 studies in Atherosclerosis by Novartis are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Atherosclerosis by Novartis, or all of them as a file.
02

Study summary

This study is an open label, randomized, prospective, type I hybrid effectiveness- implementation, pragmatic clinical trial to evaluate the impact of a targeted lipid optimization program on LDL-C control in participants with dyslipidemia who are at high risk or very high risk of cardiovascular events.

Read the detailed description

The treatment of interest is a lipid optimization program in the form of a health education intervention delivered via clinic visits (every 4 months) and virtual sessions (between each clinic visit).

No active drug treatment will be provided. The intervention in this study will involve the implementation of a lipid optimization, education program for patients at high risk and very high risk of cardiovascular events.

03

Conditions studied

  • Atherosclerotic Cardiovascular Disease

Keywords

  • Dyslipidemia,
  • ASCVD,
  • lipid optimization program,
  • LDL-C target,
  • educational intervention,
  • hybrid effectiveness-implementation study
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of ASCVD (coronary heart disease, peripheral arterial disease and/or cerebrovascular disease)
  • High risk or very high risk for cardiovascular events (as per the 2019 ESC/EAS guidelines [1] for the management of dyslipidemias)
  • Lipid levels:

    • High risk: LDL-C ≥70 mg/dl (or > 1.8 mmol/L) or non-HDL-C ≥100 mg/dl
    • Very high risk: LDL-C ≥55 mg/dl (or > 1.4 mmol/L) or non-HDL-C ≥85 mg/dl
  • Male or Female
  • 18 years or older
  • Seen by a specialist who is prescribing advanced lipid lowering treatments (LLTs) (cardiologist, endocrinologist or any other relevant specialist)
  • Currently taking maximum-tolerated statins
  • Ability to participate in educational program (must be able to watch online videos)
  • Capable of giving signed which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion criteria

Exclusion Criteria:

  • Any surgical or medical condition, which in the opinion of the Investigator, may place the participant at higher risk from his/her participation in the study, or is likely to prevent the participant from complying with the requirements of the study or completing the study.
  • Unwillingness or inability (e.g., physical or cognitive) to comply with study procedures (including adherence to study visits).
  • Participation in any other interventional study.
  • Inability to travel to study sites for in-person clinic visits.
  • Responsible physician clinical decision not to engage the identified patient.
  • Refusal of the potential participant to sign the consent and be included in the model.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
326 participants (estimated)

Study arms

  • Other
    Intervention group

    Participants receive Health Education Intervention alongside standard of care

    Other: Educational Material · Other: Standard of care

  • Other
    Control Group

    Participants receive Standard of care

    Other: Standard of care

Interventions

  • OtherEducational Material

    Health Education Intervention delivered via clinic visits (every 4 months) and virtual sessions (between each clinic visit)

  • OtherStandard of care

    Standard of care

06

What researchers measure

Primary outcomes

  1. Percentage of participants achieving target LDL-C goals based on CV risk

    Percentage of participants achieving target Low-Density Lipoprotein Cholesterol (LDL-C) goals based on Cardiovascular (CV) risk stratified by group: * Very high risk: \<55 mg/dl * High risk: \<70 mg/dl

    Time frame: Baseline, month 12

Secondary outcomes

  1. Percentage of participants achieving or maintaining target LDL-C goals based on CV risk

    Percentage of participants achieving or maintaining target Low-Density Lipoprotein Cholesterol (LDL-C) goals based on Cardiovascular (CV) risk stratified by group: * Very high risk: \<55 mg/dl * High risk: \<70 mg/dl

    Time frame: Baseline, month 24

  2. Change of LDL-C

    Change of Low-Density Lipoprotein Cholesterol (LDL-C) from baseline at 12 months and 24 months in both study groups

    Time frame: Baseline, month 12 and month 24

  3. Change in the proportion of participants receiving advanced lipid lowering therapies

    Change in the proportion of participants receiving advanced lipid lowering therapies at 12 months and 24 months from baseline, for each group

    Time frame: Month 12 and Month 24

  4. Proportion of participants from the intervention group who complete all visits

    Proportion of participants from the intervention group who complete all: * In clinic visits * Virtual sessions

    Time frame: 24 months

  5. Proportion of participants from the intervention group who discontinue the education program

    Proportion of participants from the intervention group who discontinue the education program before the 12 month study visit

    Time frame: 12 months

  6. Proportion of days covered

    Proportion of days covered (for statins and non-statin lipid therapies)

    Time frame: Baseline, month 12 and month 24

  7. Number of hospitalizations

    Number of hospitalizations during the 12 month active intervention period and the 12 month follow up period

    Time frame: 24 months

  8. Number of outpatient visits

    Number of outpatient visits during the 12 month active intervention period and the 12 month follow up period

    Time frame: 24 months

  9. Number of ER visits

    Number of Emergency Room (ER) visits during the 12 month active intervention period and the 12 month follow up period

    Time frame: 24 months

  10. Associated costs

    Associated costs during the 12 month active intervention period and the 12 month follow up period

    Time frame: 24 months

  11. Number of LDL-C tests performed

    Number of Low-Density Lipoprotein Cholesterol (LDL-C) tests performed, analyzed according to: * Site (clinic) * Healthcare Professional (HCP) specialty (Cardiologists, Endocrinologists, internist, etc.) * Baseline characteristics (e.g. age, sex, ethnicity, Cardiovascular risk status)

    Time frame: 24 months

  12. Change in knowledge awareness scores:

    Awareness regarding lipid management amongst those participants in the intervention group will be measured using a knowledge awareness questionnaire. The same questionnaire will be administered at baseline, 12 months and 24 months, enabling scores to be compared across the study duration. The knowledge awareness questionnaire scale has a minimum score of 0 and maximum score of 17 points. A high score will indicate higher participant awareness.

    Time frame: Baseline, month 12 and month 24

  13. Change in WHO BREF quality of life scores

    WHO BREF questionnaire assesses QoL across four main domains: physical health, psychological health, social relationships, and environmental health. Participants will respond to each item using a Likert scale (ranging from 1 to 5) indicating their level of agreement or satisfaction. Higher scores typically indicate better QoL.

    Time frame: Baseline, month 12 and month 24

  14. Qualitative surveys among focus groups of HCPs and participants to evaluate implementation outcomes

    Implementability of the lipid optimization program will be assessed during focus group sessions that explore satisfaction, costs, and acceptance of the program from the perspective of HCPs and participants

    Time frame: month 12 and month 24

07

Study locations

1 of 1 sites recruiting
  • Novartis Investigative Site
    Abu Dhabi, United Arab Emirates
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for May 2027, 18 months after the start.

Of 55 phase 4 interventional studies under Atherosclerosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 59. This study's planned 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2025
First posted
Jun 24, 2025
StartActual
Nov 26, 2025
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2028
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07034690
Responsible party
Sponsor
First posted
Jun 24, 2025
Start date
Nov 26, 2025
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2028 (estimated)
Last update
May 4, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion